An Open Label Study to Evaluate the Safety and Efficacy of BOR15001L7 for the Treatment of Cold Sores in Patients With Recurrent Herpes Labialis

Recurrent Herpes Labialis Clinical Trial

Official title:

A Randomized, Open Label, Non-inferiority Study to Compare the Safety and Efficacy of BOR15001L7 to Docosanol 10% in Patients With Recurrent Herpes Labialis

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03977792
• Other study ID #: BOR-15001L7-P2
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: September 2020
• Est. completion date: July 2022

Study information

• Verified date: September 2020
• Source: Laboratoire Boreaderme Inc.
• Contact: Etienne Khoury, PhD, CCRP
• Phone: (418) 545-1252
• Email: etienne.khoury[@]ecogene21.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

BOR15001L7 is a natural product. The primary objective of this study is to demonstrate its non-inferiority to docosanol 10% based on the healing time of cold sores in patients with recurrent herpes labialis.

Description:

Secondary objectives are to:

1. Evaluate the efficacy of BOR1500L7 on:

• The reduction of ulcerative lesions rates following the prodromal stage;

• The extension of the delay prior to first ulcerative lesions occurence following the prodromal stage;

• The decrease of cumulative ulcerative lesions dimensions during papule, vesicles, ulcers/soft and hard crust stages;

• The decrease of symptoms intensity (pain, tingling, itching, burning sensation) during prodromal, erythema, papule, vesicles, ulcers/soft crust, hard crust, re-epithelialize stages;

• The reduction of symptoms duration (pain, tingling, itching, burning sensation) during the prodromal, erythema, papule, vesicles, ulcers/soft crust, hard crust, re-epithelialize stages in subjects with recurrent herpes labialis;

2. Evaluate the safety and tolerability of BOR15001L7 in subjects with recurrent herpes labialis

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 164
• Est. completion date: July 2022
• Est. primary completion date: July 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Provide signed informed consent and willing to comply with study-related procedures;

• Males and females =18 years of age at screening;

• Diagnosed with recurrent herpes labialis, defined as showing at least 2 episodes of infections per year;

• Willing to avoid, during the treatment phase, the use of anti-inflammatory, anti-herpetic, antibiotic and antiviral agents as well as steroids or other natural products that would interfere with the immune system response (exception: only the use of valacyclovir will be permitted, if prescribed);

• Willing to avoid, during the treatment phase, the use of cosmetic products (ex. cream, make-up, etc.) at areas close to the infected region.

Exclusion Criteria:

• Patients with skin disease affecting the peribuccal region (eczema, psoriasis, dermatitis, etc.);

• Patients with herpes labialis occurring within 14 days prior to screening;

• Patients known for allergies or intolerance to drug and comparator ingredients, or any cream used to treat skin conditions;

• Treatment with an investigational product or biological agent or device within 30 days or five half?lives, whichever is longer.

• Any other condition, which, in the opinion of the investigator or the sponsor would make the patient unsuitable for inclusion, or could interfere with the conduct of the study.

Related Conditions & MeSH terms

• Herpes Labialis
• Recurrent Herpes Labialis

Intervention

Drug:
• BOR15001L7
BOR15001L7 topically applied to infected area, 5 times a day, until complete healing of the infection.
• Docosanol Cream 10%
Comparator product topically applied to infected area, 5 times a day, until complete healing of the infection.

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Laboratoire Boreaderme Inc.	Ecogene 21

References & Publications (1)

Lavoie S, Côté I, Pichette A, Gauthier C, Ouellet M, Nagau-Lavoie F, Mshvildadze V, Legault J. Chemical composition and anti-herpes simplex virus type 1 (HSV-1) activity of extracts from Cornus canadensis. BMC Complement Altern Med. 2017 Feb 22;17(1):123. doi: 10.1186/s12906-017-1618-2. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The mean change of healing time		Day 1 to 12
Secondary	The change in lesion rates following the prodromal stage		Day 1 to 12
Secondary	The mean change in delays (hours) between the prodromal stage and the first visible occurence of lesions		Day 1 to 12
Secondary	The percentage change in number of lesions at papule, vesicles and ulcers/soft crust, hard crust stages		Day 1 to 12
Secondary	The percentage change in dimensions (mm) of lesions at papule, vesicles and ulcers/soft crust, hard crust stages		Day 1 to 12
Secondary	The percentage of patients that demonstrated a change in intensity of drug-related symptoms (pain, tingling, itching, burning sensation) at papule, vesicles and ulcers/soft crust, hard crust stages		Day 1 to 12
Secondary	The mean change in duration (hours) of drug-related symptoms (pain, tingling, itching, burning sensation) at papule, vesicles and ulcers/soft crust, hard crust stages		Day 1 to 12
Secondary	Safety and tolerability measured by the Incidence of Treatment-Emergent Adverse Events [Side-effects]		Day 1 to 12